Related Experiment Videos
Chemotherapy for advanced hormone refractory prostate cancer
1Genitourinary Oncology Program, Division of Medical Oncology, Columbia Presbyterian Medical Center, New York, New York 10032, USA.
Urology
|December 22, 1999
Summary
Men with metastatic prostate cancer progressing after hormone therapy have limited options. New treatments targeting apoptosis pathways and chemotherapy combinations show promise for hormone-refractory prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Metastatic prostate cancer often responds to androgen ablation but eventually becomes hormone-refractory.
- Limited treatment options exist for patients who progress after initial hormone therapy.
- Apoptosis pathways are a focus for treating hormone-resistant prostate cancer.
Purpose of the Study:
- To review current and emerging treatment strategies for hormone-refractory prostate cancer.
- To highlight the role of apoptosis and chemotherapy in managing advanced prostate cancer.
Main Methods:
- Review of recent studies on anticancer drug mechanisms and apoptosis.
- Analysis of clinical trial data for chemotherapy combinations in hormone-refractory prostate cancer.
- Examination of FDA approvals and treatment guidelines.
Main Results:
- Chemotherapy, such as mitoxantrone and prednisone, can palliate bone pain in hormone-refractory prostate cancer.
- Combinations like estramustine with vinblastine (VP-16) show significant prostate-specific antigen (PSA) declines.
- In vitro studies suggest taxane combinations (paclitaxel, docetaxel) enhance cytotoxicity.
Conclusions:
- Chemotherapy offers palliative benefits and can induce PSA declines in hormone-refractory prostate cancer.
- Targeting apoptosis pathways represents a promising avenue for novel therapies.
- Further phase III trials are needed to confirm the efficacy of taxane-based therapies.